Monika Rau1, Ateequr Rehman2, Marcus Dittrich3, Albert K Groen4, Heike M Hermanns1, Florian Seyfried5, Niklas Beyersdorf6, Thomas Dandekar3, Philip Rosenstiel2, Andreas Geier1. 1. Department of Medicine II, Division of Hepatology, University Hospital Würzburg, Germany. 2. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Germany. 3. Department of Bioinformatics, Biocenter, University of Würzburg, Germany. 4. Department of Pediatrics/Laboratory Medicine, UMCG, Groningen, The Netherlands. 5. Department of General and Visceral Surgery, University Hospital Würzburg, Germany. 6. Institute for Virology and Immunobiology, University of Würzburg, Germany.
Abstract
BACKGROUND: Intestinal microbiota and their metabolites (e.g. short-chain fatty acids (SCFAs)) may influence nonalcoholic fatty liver disease (NAFLD). OBJECTIVE: The objective of this article is to analyze gut bacterial diversity together with fecal SCFA concentrations and immunophenotyping of peripheral blood in histology-proven NAFLD patients. METHODS: Thirty-two NAFLD patients (14 nonalcoholic fatty liver (NAFL), 18 nonalcoholic steatohepatitis (NASH)) and 27 healthy controls (HCs)) were included in this study. Bacterial communities in feces were profiled by 16S ribosomal RNA gene sequencing of the V3-V4 region. Fecal SCFA levels were analyzed by high-performance liquid chromatography. Fluorescence-activated cell sorting analysis was performed of peripheral blood mononuclear cells. RESULTS: NASH patients were characterized by higher abundance of Fusobacteria and Fusobacteriaceae compared to NAFL and HCs. Conforming to our finding that NAFLD patients had higher fecal acetate and propionate levels, taxonomical differences of fecal bacteria were dominated by SCFA-producing bacteria. Higher fecal propionate and acetate levels were associated with lower resting regulatory T-cells (rTregs) (CD4+CD45RA+CD25++) as well as higher Th17/rTreg ratio in peripheral blood as immunological characteristics of NASH patients. CONCLUSIONS: NASH patients are characterized by a different gut microbiome composition with higher fecal SCFA levels and higher abundance of SCFA-producing bacteria in NAFLD. These changes are associated with immunological features of disease progression. Our data suggest an important role of the intestinal microbiome and immunomodulatory bacterial metabolites in human NAFLD.
BACKGROUND: Intestinal microbiota and their metabolites (e.g. short-chain fatty acids (SCFAs)) may influence nonalcoholic fatty liver disease (NAFLD). OBJECTIVE: The objective of this article is to analyze gut bacterial diversity together with fecal SCFA concentrations and immunophenotyping of peripheral blood in histology-proven NAFLD patients. METHODS: Thirty-two NAFLD patients (14 nonalcoholic fatty liver (NAFL), 18 nonalcoholic steatohepatitis (NASH)) and 27 healthy controls (HCs)) were included in this study. Bacterial communities in feces were profiled by 16S ribosomal RNA gene sequencing of the V3-V4 region. Fecal SCFA levels were analyzed by high-performance liquid chromatography. Fluorescence-activated cell sorting analysis was performed of peripheral blood mononuclear cells. RESULTS: NASH patients were characterized by higher abundance of Fusobacteria and Fusobacteriaceae compared to NAFL and HCs. Conforming to our finding that NAFLD patients had higher fecal acetate and propionate levels, taxonomical differences of fecal bacteria were dominated by SCFA-producing bacteria. Higher fecal propionate and acetate levels were associated with lower resting regulatory T-cells (rTregs) (CD4+CD45RA+CD25++) as well as higher Th17/rTreg ratio in peripheral blood as immunological characteristics of NASH patients. CONCLUSIONS: NASH patients are characterized by a different gut microbiome composition with higher fecal SCFA levels and higher abundance of SCFA-producing bacteria in NAFLD. These changes are associated with immunological features of disease progression. Our data suggest an important role of the intestinal microbiome and immunomodulatory bacterial metabolites in human NAFLD.
Authors: Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp Journal: Gastroenterology Date: 2012-06-20 Impact factor: 22.682
Authors: Patrick D Schloss; Sarah L Westcott; Thomas Ryabin; Justine R Hall; Martin Hartmann; Emily B Hollister; Ryan A Lesniewski; Brian B Oakley; Donovan H Parks; Courtney J Robinson; Jason W Sahl; Blaz Stres; Gerhard G Thallinger; David J Van Horn; Carolyn F Weber Journal: Appl Environ Microbiol Date: 2009-10-02 Impact factor: 4.792
Authors: Tatiana F S Teixeira; Łukasz Grześkowiak; Sylvia C C Franceschini; Josefina Bressan; Célia L L F Ferreira; Maria C G Peluzio Journal: Br J Nutr Date: 2012-07-04 Impact factor: 3.718
Authors: Lixin Zhu; Susan S Baker; Chelsea Gill; Wensheng Liu; Razan Alkhouri; Robert D Baker; Steven R Gill Journal: Hepatology Date: 2013-01-08 Impact factor: 17.425
Authors: S De Baere; V Eeckhaut; M Steppe; C De Maesschalck; P De Backer; F Van Immerseel; S Croubels Journal: J Pharm Biomed Anal Date: 2013-02-28 Impact factor: 3.935
Authors: Marialena Mouzaki; Elena M Comelli; Bianca M Arendt; Julia Bonengel; Scott K Fung; Sandra E Fischer; Ian D McGilvray; Johane P Allard Journal: Hepatology Date: 2013-05-14 Impact factor: 17.425
Authors: Craig Lammert; Andrea S Shin; Huiping Xu; Christopher Hemmerich; Thomas M O'Connell; Naga Chalasani Journal: FEMS Microbiol Lett Date: 2021-04-22 Impact factor: 2.742
Authors: Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula Journal: Biomedicines Date: 2021-12-31